DTIL Precision Biosciences Inc

$DTIL In short: CRISPR acts like a molecular pair of scissors that cuts blindly, relying on the cell to patch up the mess. ARCUS acts more like a cohesive all-in-one software package that makes clean, jagged cuts engineered for complex edits like inserting or excising whole chunks of DNA with high precision. I will take a Dose of ARCUS please. No Brainer

Press Release from 10/8: ​Michael S. Weiss, Chairman and Chief Executive Officer of TG Therapeutics , stated, “We are extremely pleased that the first clinical results from our azer-cel program in progressive multiple sclerosis have been selected for a late-breaking oral presentation at MSToronto2026.$DTIL

More positive news today from $DTIL partner Imugene on their P1b Azer-Cell trial. Another complete response and one partial response. Immugene is gonna need to find a partner or flip this back to Precision but great news. Overall Response Rate now at 71%.

$DTIL — Precision BioSciences is taking gene editing in a different direction with its ARCUS platform. Rather than being another CRISPR company, ARCUS uses a distinct type of programmable nuclease designed for precise DNA editing. DTIL is presenting at this week’s cell and gene-therapy conference, and I’m watching for updates on clinical development and partnerships. Different editing technology + a small valuation makes this an interesting speculative biotech to research.

$DTIL Expecting additional biopsy data, hopefully from the higher dose cohort, but even the low dose was pretty spectacular.

$DTIL The AASLD The Liver Meeting 2026 will take place from Thursday, November 5, to Monday, November 9, 2026, at the Colorado Convention Center in Denver, Colorado

$DTIL First Clinical Evaluation of an Allogeneic CD19-Directed CAR T-Cell Therapy in Progressive Multiple Sclerosis: Initial Results From the Phase 1 TG-Azercel-101 Study MS Toronto 2026 Oct 23